Diabetes Therapy

Aims & Scope

Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes.

Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.

The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters.

The journal is read by a global audience and receives submissions from all over the world.

Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data.

Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations.

This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	2.6
2024	2.80

SJR (SCImago Journal Rank)

Year	Value
2024	1.070

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	59

Journal Rank

Year	Value
2024	4321

Journal Citation Indicator

Year	Value
2024	1534

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

---

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Adherence to Therapies in Patients with Type 2 Diabetes

  Citation: 510

  Authors: Luis-Emilio, María, Tatiana, Vicente, Domingo

• Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial

  Citation: 494

  Authors: Thomas, Hélène, Ramzi, Norbert, Jean-Pierre, Gerry

• Management of Diabetic Foot Ulcers

  Citation: 359

  Authors: Kleopatra, John

• A Practical Review of C-Peptide Testing in Diabetes

  Citation: 318

  Authors: Emma, Christopher AR, Gregory C.

• Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study

  Citation: 311

  Authors: Sarah J., Amy L., Paul T., Nasir H., Anne L., Wayne W., Tamara L., Brittanie M., James P., Stephen D., Jeff S.

• Diabetes Dyslipidemia

  Citation: 278

  Authors: Jonathan D., Yifen, Prasanna, Rayaz A., Handrean

• Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology

  Citation: 253

  Authors: Sanjay

• Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members

  Citation: 249

  Authors: Jian, Sandy, Samantha, Howard, Deborah, Jean M., John N.

• The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials

  Citation: 209

  Authors: Thinzar, Stephen C.

• Prevalence and Risk Factors for Diabetes Mellitus in Nigeria: A Systematic Review and Meta-Analysis

  Citation: 208

  Authors: Andrew E., Baba M., Mansur A., Ibrahim D., Fabian H., Ayekame T., Musa M., Kabiru B.

---